Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2011
|
| Subjects: | |
| Online Access: | https://doaj.org/article/7beb2246337149e8b59df7e8f7bc3c5c |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!